References: Enhertu® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease ...

Geriatric Use: Of the 1287 patients with HER2-positive or HER2-low breast cancer treated with ENHERTU 5.4 mg/kg, 22% were ≥65 years and 3.8% were ≥75 years.

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In 2022, the drug became the first therapy approved for HER2-low breast ...

AstraZeneca and Daiichi Sankyo’ s ENHERTU ® has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor- positive, HER2-low or HER2-ultralow ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

The application for Priority Review of Enhertu was supported by positive results from the DESTINY-Breast06 Phase III trial, which demonstrated that Enhertu reduced the risk of disease progression or ...

According to the press release from Daiichi Sankyo, it is estimated that approximately 60-65% of HR-positive, HER2-negative breast cancers are HER2-low. Up to 25% may also be HER2-ultralow. In 2022, ...

DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings ...

TOKYO & MUNICH, February 28, 2025--ENHERTU® Recommended for Approval in the EU by CHMP for HER2 Low or Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy ...